

ИЗПОЛЗВАНА ЛИТЕРАТУРА

1. Апостолов М., П. Иванова. История на медицината и сестринството. ГорексПрес, София, 1998.
2. Атанасов Н. и съавт. Въведение в „Медицина основана на доказателства“. ИК-ВАП, Пловдив, 2004.
3. Грънчарова Г., А. Велкова, С. Александрова-Янкуловска. Социална медицина, 3^{то} изд. ИЦ на МУ-Плевен, Плевен, 2009.
4. Ново обществено здравеопазване (под ред. В. Борисов, З. Глутникова, Ц. Воденичаров), Акваграфикс, София, 1998.
5. Съвременна епидемиология. (под ред. Н. Фесчиева). Конквиста, Варна, 1997.
6. Шипковенска Е. (ред.), Ж. Христов, П. Димитров, М. Дякова. Модерна епидемиология с медицина и здравеопазване, базирани на доказателства. Филвест, София, 2008.
7. Шипковенска Е. Съречно-съдов риск – проблем с много неизвестни (Sofia Heart Study). Филвест, София, 2004.
8. Шипковенска Е., Л. Георгиева, Г. Генчев, П. Димитров. Приложна епидемиология и медицина, базирана на доказателства. Делфи, София, 2002.
9. Albrecht G., Freeman S., Higginbotham N. Complexity and human health: the case for a transdisciplinary paradigm. *Cult Med Psychiatry*, 1998, **22**, 55-92.
10. Anderson K.M., Castelli W.P., Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. *JAMA*, 1987, **257**, 2176–2180.
11. Atwood K., Colditz G.A., Kawachi I. From public health science to prevention policy: placing science in its social and political contexts. *Am J Public Health*, 1997, **87**, 10, 1603–1606.
12. Barker D.J.P., Hall A.J. *Practical epidemiology*. 4th ed. Churchill Livingstone, New York, 1991.
13. Beaglehole R., Bonita R., Kjellström T. *Basic Epidemiology*. 2nd ed., Geneva: World Health Organization. 2006.
14. Beaglehole R., Bonita R., Kjellström T. *Basic Epidemiology*., Geneva: World Health Organization. 1993.
15. Benson K., Hartz A.J. A comparison of observational studies and randomized, controlled trials. *N Engl J Med*, 2000, **342**, 1878–1886.
16. Bernstein L. Control recruitment in population-based case-control studies. *Epidemiology*, 2006, **17**, 255-257.
17. Boyes D.A., Nichols T.M., Millner A.M., Worth A.J. Recent results from the British Columbia screening program for cervical cancer. *Am J Obstet Gynecol*, 1977, **128**, 692-693.
18. Casselli G., Mesle F., Vallin J. Epidemiologic transition theory exceptions, *J Popul Sci*, 2002, **9**, 9–51.
19. Cates W. *Epidemiology: Applying principles to clinical practice*. *Contemp Ob/Gyn*, 1982, **20**, 147–161.

20. CDC. Principles of epidemiology in Public Health practice. 3rd ed., www.cdc.gov/osels/scientific_edu/ss1978/
21. Cochrane A.L. Effectiveness and Efficiency. Random Reflections on Health Services. London: Nuffield provincial Provinces Trust, 1972.
22. Colditz G.A., Hankinson S.E. The Nurses' Health Study: lifestyle and health among women. *Nat Rev Cancer*, 2005, **5**, 388-396.
23. Colditz G.A., Martin P., Stampfer M.J. et al. Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. *Am J Epidemiol*, 1986, **123**, 894-900.
24. Colditz G.A.: The Nurses' Health Study: a cohort of US women followed since 1976. *J Am Med Womens Assoc*. 1995, **50**, 40-44.
25. Colwell R.R. Biocomplexity and a new public health domain. *EcoHealth*, 2004, **1**, 6-7.
26. Court Brown W.M., Doll R. Leukaemia and aplastic anaemia in patients irradiated for ankylosing spondylitis. London: HMSO, 1957. (Med Res Council Special Report Series; No. 295).
27. Doll R. Cohort studies: history of the method I. prospective cohort studies. *Soz.–Präventivmed*, 2001, **46**, 75–86.
28. Doll R. Cohort studies: history of the method II. Retrospective cohort studies. *Soz.–Präventivmed*, 2001, **46**, 152–160.
29. Doll R., Hill A.B. Smoking and carcinoma of the lung. *BMJ*, 1950, **2**, 739–748.
30. Doll R., Hill A.B. The mortality of doctors in relation to their smoking habits; a preliminary report. *BMJ*, 1954, **1**, 1451–1455.
31. Doll R., Peto R., Boreham J., Sutherland I. Mortality in relation to smoking: 50 years' observations on British doctors. *BMJ*, 2004, **328**, 1519-1528.
32. Feinstein A.R. Experimental requirements and scientific principles in case-control studies. Editorial. *J Chron Dis*, 1985, **38**, 127-134.
33. Fergusson D., Glass K.C., Waring D., Shapiro S. Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials. *BMJ*, 2004, **328**, 432.
34. Fletcher R.H., Fletcher S.W., Wagner E.H. *Clinical epidemiology: the essentials*. 3rd ed. Williams & Wilkins, New York, 1996.
35. Fortmann S.P., Flora J.A., Winkleby M.A. et al. Community intervention trials: reflections on the Stanford Five-City Project Experience. *Am J Epidemiol*, 1995, **142**, 576-586.
36. Franco G. Ramazzini and workers' health. *Lancet*, 1999, **354**, 858-861.
37. Fraser D., Tsai T.R., Orenstein W. et al. Legionnaires' disease: description of an epidemic of pneumonia. *New Engl J Med*, 1977, **297**, 1189–1197.
38. Frenk J., Bobadilla J.L., Sepulveda J. The health transition in Mexico: a proper model. *Demos*, 1988, 28-29.
39. Frenk J., Bobadilla J.L., Stern C. et al. Elements for a theory of the health transition. *Health Transit Rev*, 1991, **1**, 1, 21-38.
40. Freud K.M., Belanger A.J., D'Agostino R.B., Kannel W.B. The health risks of smoking: the Framingham study: 34 years of followup. *Ann Epidemiol*, 1993, **3**, 417–424.
41. Friedman G.D. *Primer of Epidemiology*. 4th ed., 1994, McGraw-Hill Inc., New York.
42. Frost W.H. The age selection of mortality from tuberculosis in successive decades. *Am J Hyg*, 1939, **30**, 91–96.



43. Gordon J.E. Epidemiology in modeim perspective. Proceed R Soc Med, 1954, **22**, 564-570.
44. Gottlieb M.S., Schroff R., Schanker H.M. et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual bmen: evidence of a new acquired cellular immunodeficiency. New Engl J Med. 1981, **305**, 1425-1431.
45. Greenland S., Robins J. Accepting the limits of ecologic studies. Am J Epidemiol, 1994, **139**, 769-771.
46. Greenwood M. Epidemics and crowd-diseases: an introduction to the study of epidemiology, Oxford University Press, 1935.
47. Gribble J.N., Preston S.H. The epidemiological transition: Policy and planning implications for developing countries. National Academy Press, Washington, DC, 1993.
48. Grimes D.A., Schulz K.F. Bias and causal associations in observational research. Lancet, 2002, **359**, 248-252.
49. Guyatt G.H., Oxman A.D., Vist G.E. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008, **336**, 924-926.
50. Hackshaw A.K., Law M.R., Wald N.J. The accumulated evidence on lung cancer and environmental tobacco smoke. BMJ, 1997, **315**, 980-988.
51. Hennekens C.H. and Buring J.E. Epidemiology in Medicine. Little, Brown and Company Boston/Toronto. USA, First Edition, 1987, 383.
52. Hennekens C.H., Buring J.E., Manson J.E. et al. Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. New Engl J Med, 1996, **334**, 1145-1149.
53. Hill A.B. The environment and disease: association or causation? Proc R Soc Med, 1965, **58**, 295-300.
54. Holland W.W., Olsen J., du V. Florey Ch. (eds.). The development of modern epidemiology: personal reports from those who were there. Oxford University Press, New York, 2007.
55. Howick J., Glasziou P., Aronson J.K. The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? J R Soc Med, 2009, **102**, 186-194.
56. Hróbjartsson A., Forfang E., Haahr M.T et al. Blinded trials taken to the test: an analysis of randomized clinical trials that report tests for the success of blinding. Int J Epidemiol, 2007, **36**, 654-663.
57. Hugberg U., Wall S. Secular trends in maternal mortality in Sweden from 1750 to 1980. Bull WHO, 1986, **64**, 79-84.
58. Jadad A.R., Cook D.J., Jones A. et al. Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals. JAMA, 1998, **280**, 278-280.
59. Jamison D.T., Breman J.G., Measham A.R. et al (eds). Disease control priorities in developing countries, 2nd ed. Oxford University Press, New York, 2006.
60. Kannel W. The Framingham Study: its 50-year legacy and future promise. J Atheroscler Thromb, 2000, **6**, 60-66.
61. Katz I.T., Wright A.A. Preventing cervical cancer in the developing world. N Engl J Med, 2006, **354**, 1110.
62. Koplan J.P., Thacker S.B., Lezin N.A. Epidemiology in the 21st century: calculation, communication, and intervention. Am J Public Health, 1999, **89**, 1153-1155.

63. Kramer M.S., Boivin J.F. Directionality, timing and sample selection in epidemiologic research designs. *J Clin Epid*, 1989, **42**, 827–828.
64. Krieger N. Commentary: Ways of asking and ways of living: reflections on the 50th anniversary of Morris' ever-useful Uses of Epidemiology. *Int J Epidemiol*, 2007, **36**, 1173–1180.
65. Krieger N. Epidemiology and the web of causation: has anyone seen the spider? *Soc Sci Med*, 1994, **39**, 887–903.
66. Lane-Clayton J (A further report on cancer of the breast. London: Ministry of Health. Reports on public health and medical subjects; 32, 1926.
67. Last J.M., ed. Dictionary of epidemiology. 4th ed. Oxford University Press, New York, 2001.
68. Last J.M., Public health and human ecology. 2nd ed. McGraw-Hill, New York, 1997.
69. Liddell F.D.K. The development of cohort studies in epidemiology: a review. *J Clin Epidemiol*, 1988, **41**, 1217–1237.
70. Lilienfeld A.M., Lilienfeld D.E. Foundations of epidemiology, 2nd ed. Oxford University Press, New York, 1980.
71. Lilienfeld D.E., Gallo M.A. 2,4-D, 2,4,5-T, and 2,3,7,8-TCDD: an overview. *Epidemiological review*, 1989, **11**, 28-58.
72. Lloyd-Jones D.M., Leip E.P., Larson M.G. et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. *Circulation*. 2006, **113**, 791-798.
73. Lopez A.D., Mathers C.D., Ezzati M. et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. *Lancet*, 2006, **367**, 1747-1757.
74. Mackenbach J.P. The epidemiologic transition theory. Editorials. *JECH*, 1994, **48**, 329-331.
75. MacMahon B., Pugh T.F., Ipsen J. Epidemiologic methods. Little, Brown and Company, Boston, 1960.
76. Marmot M. Social determinants of health inequalities. *Lancet*, 2005, **365**, 1099-1104.
77. Mascie-Taylor C.G.N., Peters J., McGarvey S.T. (eds.). The changing face of disease: implications for society, Florida: CRC Press, 2004.
78. McKeown T. The role of medicine: dream, mirage or nemesis? London, Nuffield Provincial Hospitals Trust, 1976.
79. McMichael A.J, McKee M., Shkolnikov V., Valkonen T. Mortality trends and setbacks: Global convergence or divergence? *Lancet*, 2004, **363**, 1155–1159.
80. McMichael A.J., Campbell-Lendrum D.H., Corvalan C.F. et al. Climate change and human health, risks and responses. Geneva, World Health Organization, 2003.
81. McMichael A.J., Woodruff R. Detecting the health effects of environmental change: scientific and political challenge. *Ecohealth*, 2005, **2**, 1-3.
82. Mellin G.W., Katzenstein M. The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. *N Engl J Med*, 1962, **267**, 1238-1244.
83. Miettinen O.S. The clinical trial as paradigm for epidemiologic research. *J Clin Epidemiol*, 1989, **42**, 6, 491-496.
84. Miettinen O.S. Theoretical epidemiology, Wiley, New York, 1985.



85. Modab B., Lilienfeld A.M. Polycytemia vera and leukemia – the rple of radiation treatment. *Medicine*, 1965, **44**, 305-344.
86. Morris J.N. *Uses of epidemiology*. Edinburgh: Livingstone; 1957.
87. Nelson N.J. Nurses' Health Study: Nurses helping science and themselves. *JNCI*, 2000, **92**, 8, 597-599.
88. Norell S.E. *A short course in epidemiology*. Raven Press Ltd, New York, 1992.
89. Olsen J., Saracci R., Trichopoulos D. *Teaching Epidemiology: A guide for teachers in epidemiology, public health and clinical medicine*. 3rd ed., Oxford University Press, 2012.
90. Paneth N., Susser E., Susser M. Origins and early development of the case-control study: part 2, The case-control study from Lane-Claypon to 1950. *Soz.– Präventivmed*, 2002, **47**, 359–365.
91. Paneth N., Susser E., Susser M. Origins and early development of the case-control study: part 1, Early evolution. *Soz.– Präventivmed*, 2002, **47**, 282–288.
92. Pearce N. Epidemiology as a population science. *Int J Epidemiol*, 1999, **28**, S1015–S1018.
93. Pearce N. The globalization of epidemiology: introductory remarks. *Int J Epidemiol*, 2004, **33**, 1127-1131.
94. Pearce N. Traditional epidemiology, modern epidemiology, and public health. *Am J Public Health*, 1996, **86**, 678–683.
95. Peto R., Lopez A.D., Boreham J., Thun J. *Mortality from smoking in developed countries*, 2nd ed. Oxford University Press, Oxford, 2003.
96. Phillips C.V., Goodman K.J. The missed lessons of Sir Austin Bradford Hill. *Epidemiol Perspect Innov*, 2004, **1**, 3.
97. Poole C., Rothman K.J. Our conscientious objection to the epidemiology wars. *JECH*, 1998, **52**, 613-614.
98. Porta M., ed. *A dictionary of epidemiology*, 5th ed. Oxford University Press, New York, 2008.
99. Puska P. Successful prevention of non-communicable diseases: 25 years experience with North Karelia Project in Finland. *Pub Hlth Med*, 2002, **4**, 1, 5-7.
100. Puska P. The North Karelia Project: 30 years successfully preventing chronic diseases. *Diabetes Vioce*, 2008, **53**, 26-29.
101. Rockett I.R.H. *Population and Health: An Introduction to Epidemiology*, 2nd ed., *Population Bulletin*, 1999, **54**, 4, 4-48.
102. Rose G. Sick individuals and sick populations. *Int J Epidemiol*, 1985, **14**, 32-38.
103. Rose G.A. *The strategy of preventive medicine*. Oxford University Press, Oxford, 1992.
104. Rossouw J.E., Anderson G.L., Prentice R.L. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA*, 2002, **288**, 321–333.
105. Rothman K.J. Causes. *Am J Epidemiol*, 1976, **104**, 587-592.
106. Rothman K.J. Induction and latent periods. *Am J Epidemiol*, 1981, **114**, 253-259.
107. Rothman K.J., Greenland S. Causation and causal inference in epidemiology. *Am J. Public Health*, 2005, **95**, S144-150.
108. Rothman K.J., Greenland S. *Modern Epidemiology*. Second Edition. Lippincott Williams & Wilkins, New York, 1998.

109. Sacks H.S., Berrier J., Reitman D. et al. Meta-analysis of randomised controlled trials. *N Engl J Med*, 1987, **316**, 450-455.
110. Savitz D.A. In defense of black box epidemiology. *Epidemiology*, 1994, **5**, 550-552.
111. Schoenbach V.J., Rosamond W. D. *Understanding the Fundamentals of Epidemiology an evolving text*. North Carolina, Chapel Hill, 2000.
112. Shakir S.A., Layton D. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford Hill criteria. *Drug Saf*, 2002, **25**, 467-471.
113. Shargie E.B., Morkve O., Lindtjorn B. Tuberculosis case-finding through a village outreach programme in a rural setting in southern Ethiopia: community randomized trial. *Bull WHO*, 2006, **84**, 112-119.
114. Snow J. *Snow on cholera*. London: Humphrey Milford: Oxford University Press, 1936.
115. Soskolne C.L., Butler C., IJsselmuiden C. et al. Toward a global agenda for research in environmental epidemiology. *Epidemiology and Society*, 2007, **18**, 1, 162-166.
116. Soskolne C.L., Huynen M., Ladd B.D., Martens P. Eco-epidemiological enquiry under global ecological change: an integrated assessment toolkit for beginners. <http://www.collegiumramazzini.org/gest/up/Sosklone.pdf>
117. Strong K., Mathers C., Leeder S., Beaglehole R. Preventing chronic diseases: how many lives can we save? *Lancet*, 2005, **366**, 1578-1582.
118. Susser M., Susser E. Choosing a future for epidemiology: II. From black boxes to Chinese boxes and eco-epidemiology. *Am J Public Health*, 1996, **86**, 674-677.
119. Susser M. Epidemiology in the United States after World War II: the evolution of technique. *Epidemiol Reviews*, 1985, **7**, 147-177.
120. Susser M. The logic in ecological studies: I. The logic of analysis. *AJPH*, 1994, **84**, 825-829.
121. Susser M. The logic in ecological studies: II. The logic of design. *AJPH*, 1994, **84**, 830-835.
122. Susser M. The tribulations of trials—interventions in communities. *Am J Public Health*, 1995, **85**, 156.
123. Terris M. The Society for Epidemiologic Research (SER) and the future of epidemiology. *Am J Epidemiol*, 1992, **136**, 909-915.
124. Thacker S.B. Historical development. In: Teutsch S.M., Churchill R.E., (eds.). *Principles and practice of public health surveillance*, 2nd ed. Oxford University Press, New York, 2002, 1-16.
125. Tolonen H., Dobson A., Kulathinal S. WHO MONICA Project. Assessing the quality of risk factor survey data: lessons from the WHO MONICA Project. *Eur J Cardiovasc Prev Rehabil*, 2006, **13**, 104-114.
126. Tunstall-Pedoe H., Vanuzzo D., Hobbs M. et al. Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations. *Lancet*, 2000, **355**, 688-700.
127. Tuyns A.J., Pequignot G., Jensen O.M. Esophageal cancer in Ille-et-Vilaine in relation to levels of alcohol and tobacco consumption. Risks are multiplying. *Bulletin du Cancer*, 1977, **64**, 1, 45-60.
128. U.S. Department of Health and Human Services (HHS). *Healthy people 2010*. 2nd ed. U.S. Government Printing Office, Washington, DC, 2000.



129. Victora C.G., Barros F.C., Vaughan J.P., Teixeira A.M. Birthweight and infant mortality: a longitudinal study of 5,914 Brazilian children. *Int J Epidemiol*, 1987, **16**, 239-245.
130. Wahdan M.H. The epidemiological transition. *East Medit Hlth J*, 1996, **2**, 1, 8–20.
131. Wald N.J. Guidance on medical screening. *J Med Screen*, 2001, **8**, 56.
132. Wald N.J. The epidemiological approach. An introduction to epidemiology in medicine. 4th ed. Royal Soc Medicine Press Ltd, London, 2004.
133. Wald N.J., Idle M., Boreham J., Bailey A. Low serum vitamin A and subsequent risk of cancer. *Lancet*, 1980, **2**, 813–815.
134. Wald N.J., Thompson S.G., Densem J.W. et al. Serum beta-carotene and subsequent risk from cancer: results from the BUPA study. *Brit J Cancer*, 1987, **57**, 428–433.
135. Walter S.D. Choice of effect measure for epidemiological data. *J Clin Epidemiol*, 2000, **53**, 931-939.
136. Weiss N.S. Clinical epidemiology. The study of the outcome of illness. 2nd ed. Oxford University Press, New York, 1996.
137. Whitehead M. William Farr's legacy to the study of inequalities in health. *Bull WHO*, 2000, **78**, 1, 86-87.
138. WHO. Constitution of the World Health Organization. New York, World Health Organization, 1948.
139. WHO. International Statistical Classification of Diseases and Related Health Problems. Tenth Revision. Vol. 1. Geneva, World Health Organization, 1992.
140. WHO. Preventing chronic diseases: a vital investment. Geneva, World Health Organization, 2005.
141. WHO. The World Health Report: Reducing risks, Promoting Healthy Life. Geneva, World Health Organization, 2002.
142. WHO. World Health Report 2005: Make every mother and child count. Geneva, World Health Organization, 2005.
143. Williamson J., Russo F. Interpreting causality in the health sciences. *Int Stud Philos Sci*, 2007, **21**, 157–170.
144. Winkelstein Jr. W. Interface of epidemiology and history: a commentary on past, present, and future. *Epidemiol Reviews*, 2000, **22**, 2-6.
145. Wright C., Mueller C. Screening mammography and public health policy: the need for perspective. *Lancet*, 1995, **346**, 29-32.
146. Xiaoyan L., Yin N., Zhao Y. SES health gradients during the epidemiological transition: The case of China, Discussion paper No. 4914, 2010. <http://ftp.iza.org/dp4914.pdf>.
147. Yusuf S., Hawken S., Ôunpuu S. et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet*, 2004, **364**, 937–952.
148. Zhang J., Yu K.F. What's the relative risk: a method of correcting the odds ratio in cohort studies of common outcomes. *JAMA*, 1998, **280**, 19, 1690-1691.
149. Zipperer M. HIV/AIDS prevention and control: the Cuban response. *Lancet Infect Dis*, 2005, **5**, 400.

Анжелика Велкова

Епидемиология на здравето

Българска, първо издание

Коректор:

Печатница „ЕА“ АД

Предпечатна подготовка

Печатница „ЕА“ АД

Графично оформление

Печатница „ЕА“ АД

Формат 60/84/16

Печатни коли 11